Suppr
超能文献

白细胞介素-27 攻克慢性淋巴细胞白血病的免疫抑制。

Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia.

机构信息

Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg.

Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

出版信息

Oncoimmunology. 2023 Nov 3;12(1):2276490. doi: 10.1080/2162402X.2023.2276490. eCollection 2023.

DOI:10.1080/2162402X.2023.2276490

PMID:37937211

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10627055/

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.

摘要

慢性淋巴细胞白血病（CLL）是西方世界最常见的成人白血病。它的特征是高度依赖于与周围免疫环境的相互作用，这突出了它适合免疫介导的治疗干预。我们最近发现细胞因子 IL-27 通过 T 细胞介导的机制在 CLL 中发挥强大的抗肿瘤作用。